Disclosed are substituted pyrimidinyl carboxamide compounds of formula I, salts thereof, and methods for their preparation. Specific examples of compounds of formula I include: { 6-amino-5-[(2,6-dichloro-3-fluorophenyl)ethoxy]pyridazin-3-yl} -6-morpholin-4-ylpyridin-3-yl-carboxamide, 6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-pyridazin-3 -yl-N-(pyridin-4-yl)carboxamide, and { 6-amino-5-[(2,6-dichloro-3-fluorophenyl)ethoxy]pyridazin-3-yl} -N-(1-ethyl-6-oxo-1,6-dihydro-pyridin-3-yl))carboxamide Compounds of formula I are useful for treating or preventing disease or disease symptoms associated with or mediated by protein kinase modulation activity, such as the c-met, ron or ALK or fusion proteins. Such diseases include lung, colon, breast, prostate, liver, pancreas, brain, kidney, ovaries, stomach, skin, and bone cancers, gastric, breast, pancreatic cancer, glioma, lymphoma, neuroblastoma, and hepatocellular carcinoma, papillary renal carcinoma, or head and neck squamous cell carcinoma.
